Leave after influenza;Rekonvalescens og sygemelding efter influenza

Ugeskrift for Laeger

Volumn 171, Issue 40, 2009, Pages

  Pedersen, Court ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONVALESCENCE; DISEASE TRANSMISSION; EPIDEMIC; HUMAN; INFLUENZA; MEDICAL LEAVE;

ADULT; CONVALESCENCE; DISEASE OUTBREAKS; HUMANS; INFLUENZA, HUMAN; SICK LEAVE;

EID: 70349921776     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Mølbak K, Mortensen S. De tre influenzasygdomme. Ugeskr Læger 2006:168: 265-8.
2. Nielsen LP. Influenzavaccination virker - men kun mod influenza. Ugeskr Læger 2005;162:143.
3. Meier CR, Napalkov PN, Wegmuller Y et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000;19:834-42.
4. O'Brien BJ, Goeree R, Blackhouse G et al. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness for Canada. Value Health 2003;6:116-25.
5. Imboden JB, Canter A, Cluff LE. Convalescence from influenza. Arch Intern Med 1961;108:115-21.
6. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuramidase inhibitor oseltamivir in treating acute influenza. JAMA 2000;283:1016-24.
7. The MIST (Management of Influenza in the Southern Hemisphere Trialists) study group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877-81.
8. Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuramidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999;180:254-61.
9. Cooper NJ, Sutton AJ, Abrams KR et al. Effectiveness of neuramidase inhibitors in treatment and prevention of influenza A and B: systemic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235-40.
10. Carrat F, Vergu E, Ferguson NM et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008;167:775-85.
11. Keech M, Beardsworth P. The impact of influenza on working days lost. Pharmacoeconomics 2008;26:911-24.
12. Nichol KL, D'Heilly SJ, Greenberg ME et al. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin Infect Dis 2009;48:292-8.
13. Talbird SE, Brogan AJ, Winiarski AP et al. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health-Syst Pharm 2009;469-80.